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Early mortality in cardiac light chain (AL) amyloidosis has not
changed substantially over the last 25 years, although long term
outcomes have improved.1 In addition to the physical effects of AL
ﬁbril deposition causing cardiac dysfunction, amyloidogenic light
chains are cardiotoxic, reducing contractility in cardiac myocytes,2
causing early death in zebra ﬁsh3 and reducing pharyngeal
contractility in C.elegans.4 Blocking light chain cardiotoxicity by
small molecules is attractive. Doxycycline interferes with amyloid
ﬁbril formation in a mouse model of AL amyloidosis5 and
abrogates light chain toxicity in vitro.4 Doxycycline combined
with tauroursodeoxycholic acid improved cardiac outcomes in
transthyretin amyloidosis. In a cohort of patients with systemic AL
amyloidosis, doxycycline given as antimicrobial prophylaxis post
autologous stem cell transplantation signiﬁcantly improved
survival compared to controls who were given penicillin.6 We
and others reported that treatment with highly effective
bortezomib-based chemotherapy does not improve early survival
in AL amyloidosis.7,8 Hence, an agent that directly interferes with
the amyloidogenic pathway targeting either misfolded light
chains or the amyloid ﬁbrils is needed.
We report retrospective outcomes of adding doxycycline to
standard chemotherapy in 30 patients with cardiac AL amyloidosis
compared to 73 matched controls (matched for cardiac disease
stage,9 absolute N-terminal brain natriuretic peptide (NT-proBNP)
Table 1. Baseline characteristics
Clinical characteristic All Doxycycline group Control group P-value
Age (years) 65 (41–84) 63 (41–85) 67 (41–87) 0.54
Sex (male, %) 69 (67%) 21 (70%) 48 (65%) 0.49
ECOG41 (%) 68 (67%) 26 (87%) 43 (56%)
Monoclonal protein type (%)
IgG 34 (33%) 7 (33%) 27 (37%)
IgA 12 (11%) – 12 (16%)
IgM 1 (1%) – 1 (2%)
Light chain only 34 (33%) 15 (50%) 19 (26%)
Lambda (%) 72 (69%) 22 (73%) 64 (87%)
Median dFLC (mg/l) 303 (43–3245) 367 (62–3245) 262 (62–3428) 0.34
Organ involvement (%)
Renal 63 (61%) 15 (50%) 48 (65%) 0.18
Cardiac 103 (100%) 30 (100%) 73 (100%)
Hepatic 14 (13%) 4 (13%) 10 (14%) 0.08
Peripheral nerves 7 (6%) 3 (10%) 4 (6%) 0.2
Autonomic nerves 10 (9%) 4 (13%) 6 (8%) 0.2
Gastrointestinal 8 (7%)
Soft tissue 18 (17%) 3 (10%) 15 (20%) 0.14
Other 2 (2%) 1 (3%) 1 (2%) 0.23
⩾ 2 organs involved (%) 74% 73% 56 (78%)
Median creatinine 101 (40–483) 99 (49–483) 102 (40–269) 0.82
Median eGFR 63 (15–100) 65 (15–100) 59 (22–100) 0.44
eGFRo45 ml/min (%)
Median 24 h urine protein 1.55 (0–22) 0.25 (0.1–12) 2.2 (0.1–22) 0.54
Albumin 36 (15–48) 40 (18–47) 32 (15–48) 0.001
Median alkaline phosphatase 85 (35–1028) 84 (35–593) 86(35–1028) 0.89
Median ventricular wall thickness (mm) 14.5 (13–21) 15 (12–19) 14 (12–21) 0.33
Median ejection fraction, % 55 (29–70) 55 (32–70) 55 (29–70) 0.64
Median NT-proBNP (ng/l) 4728 (559–37889) 4317 (1211–33872) 4940 (559–37889) 0.98
NT-proBNP48500 (%) 34 (33%) 8 (26%) 26 (35%) 0.49
Median HS-Troponin T 0.1 (0.003–0.95) 0.1 (0.013–0.65) 0.1 (0.003–0.95) 0.70
Median systolic BP 113 (84–157) 115 (85–144) 111 (84–157) 0.60
Mayo cardiac stage (%)
I 0 0 0
II 10 (10%) 5 (16%) 5 (7%)
III 93 (90%) 25 (83%) 68 (93%)
IIIb 34 (33%) 8 (26%) 20 (27%)
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level, age and free light chains (dFLC)). Ninety-four percent had
Mayo stage III disease (28 were Mayo stage IIIb). Table 1 shows the
baseline characteristics in both groups. An additional analysis of
patients treated with only with bortezomib-based regimes in both
arms was done. The median NT-proBNP was 4728 pmol/l
(range, 559–37 889 ng/l); high sensitivity troponin 0.1 μg/l (range,
0.032–0.95 μg/l) and dFLC 505 mg/l (range 54–3428), with no
signiﬁcant difference between either group. Doxycycline was
given 100 mg twice daily after meals. The median duration of
doxycycline was 6 months (range, 1–24 months). Initial treatment
regimens were: bortezomib, thalidomide and alkylators based in
72%, 23% and 5%, respectively. Three patients discontinued
doxycycline due to toxicity (Grade 2 photosensitive rash—2; grade
3 nausea/vomiting—1). Responses to treatment were analysed on
an intent-to-treat basis (ITT), patients who died before response
assessment were classiﬁed as non-responders. The haematologic
response on an ITT at the end of cycle 1 of chemotherapy was not
signiﬁcantly different in the group (doxycycline vs controls: very
good partial response (VGPR) or better—31% vs 29%; partial
response (PR)—31% vs 35%; no response (NR)—38% vs 32%).
The overall response rate (PR or better) on an ITT basis was
signiﬁcantly better in the doxycycline vs control groups (93% vs
59%; P= 0.001) with: complete response—56% vs 35% (P= 0.001),
VGPR—10% vs 8% (P= 0.32) and PR 30% vs 35% (P= 0.66),
respectively (Figure 1a). On an ITT basis, the median overall
survival was 13 months in the control group and not reached in
the doxycycline group. The 12 and 24 month survival in the
doxycycline vs control group was 82% vs 53% and 82% vs 40%,
respectively (Po0.0001), with marked improvement on OS for
patients with Mayo stage IIIa (Figure 1b) and high presenting
troponin T (40.1 μg/l). On an ITT, 60% of the doxycycline group,
and 18% of the control group achieved cardiac responses
(Po0.0001) (Figure 1c). Use of doxycycline remained an
independent predictor of better outcomes in ITT and 6 month
landmark analysis. When analysis was restricted to patients with a
haematologic and/or a cardiac response (80% of total in
doxycycline group vs 42% of total in the control group), at 12
and 18 months in control and doxycycline groups respectively,
75% vs 88% and 65% vs 88% were alive (log rank P = 0.24).
A total of 76 patients (26 in the doxycycline group and 50 in the
control group) were treated with upfront bortezomib-based
regime. Among the bortezomib-treated patients, there was a
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Figure 1. (a) The percentage of haematologic responders in the doxycycline and control groups. On an ITT, the overall response rate was
signiﬁcantly better in the doxycycline-treated group (the patients who died before response assessment are counted as non-responders).
However, in the landmark cohort, there is no signiﬁcant different in the haematologic responses conﬁrming that doxycycline per se does not
inﬂuence the response to chemotherapy, but only does so by allowing more patients in the treated group to live longer and achieve a
response to chemotherapy. (b) Overall survival in the doxycycline-treated and control cohorts divided by the Mayo disease stage. Patients
with very advanced cardiac stage IIIb disease (deﬁned as NT-proBNP48500 ng/l) do not have signiﬁcant improvement in survival but patients
with stage II/IIIa (NT-proBNP o8500 ng/l) have a signiﬁcant improvement in overall survival when treated with doxycycline compared to
matched controls. (c) Signiﬁcantly greater reduction in NT-proBNP after completion of treatment in the doxycycline-treated group compared
to the controls. (d) Survival of patients treated with an upfront bortezomib-based regime stratiﬁed by doxycycline vs controls. The median
survival was 15 months in the control group and was not reached in the doxycycline group (log rank P= 0.012).
Letter to the Editor
2
Blood Cancer Journal
non-signiﬁcantly greater number of haematologic responses in
the doxycycline-treated group vs controls (61% vs 46% (P= 0.23)).
However, there was still a signiﬁcant improvement in the median
survival of the doxycycline-treated group, the median survival in
the control group was 15 months vs not reached in the
doxycycline group (log rank P= 0.012; 58% vs 84% survival at
12 months respectively) (Figure 1d). In the bortezomib-treated
subgroups, there is signiﬁcantly greater decrease in NT-proBNP in
the doxycycline group compared to controls (mean decrease
5700 ng/l vs 1127 ng/l; P= 0.035).
In conclusion, this study suggests that addition of doxycycline
to standard chemotherapy reduces mortality in cardiac AL
amyloidosis. The particular impact on patients presenting with a
high troponin in particular and signiﬁcantly greater decrease in
NT-proBNP suggests that doxycycline may reduce of light chain
cardiotoxicity as one of the possible mechanisms of action. The
beneﬁt of doxycycline appeared greatest in patients with Mayo
stage IIIa disease and limited, if any, in the very advanced stage
IIIb patients. There was lack of signiﬁcant difference in the clonal
response rates between the doxycycline vs control group, at end
of one month and (for evaluable patients only) at six months.
Moreover, for the patients who survived and achieved a
haematologic response, there was only a non-signiﬁcant improve-
ment in survival in the doxycycline group at 12 and 18 months
compared to controls. This suggests that ﬁrstly, there is no direct
impact of doxycycline supplementation on the actual efﬁcacy
chemotherapy and critically, the main impact of doxycycline is
reduction in early cardiac mortality. It is reduction in the early
deaths in the doxycycline-treated group that allows greater
proportion of patients to live long enough to achieve deeper
clonal responses to chemotherapy and consequent cardiac
responses. These data need to be interpreted with caution due
to limitations of small sample size and reporting bias of small early
studies. Additionally, the exact reason for the reduction in early
mortality remains unclear—whether this is due the reduction of
the light chain toxicity, impact on other aspects of cardiac
dysfunction independent of its effect on light chains/amyloid or
indeed its antibiotic properties. Other therapies like novel
monoclonal antibodies (NEO001D10 and GSK239885211) which
accelerate clearance of amyloid deposits by activating tissue
macrophages are in advanced phase clinical trials. Since the
mechanism of action of doxycycline is likely to be different, if the
activity is conﬁrmed, it may offer synergy with therapies that clear
amyloid deposits. These encouraging early results need formal
conﬁrmation in a prospective randomised controlled trial before
this can be adopted in routine clinical practice.
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